NPCE - NASDAQ
NeuroPace, Inc.
$15.88
-2.5%NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
At a Glance
Live SnapshotNeuroPace, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
NeuroPace, Inc. Income Statement
NPCE • NASDAQ
| NeuroPace, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
100M | 79.9M | 65.4M | 45.5M | 45.2M | 41.1M | 37M | |
GROSS PROFIT | |||||||
(22.8M) | (20.8M) | (17.3M) | (13M) | (11.7M) | (10.9M) | (10.5M) | |
77.2M | 59.1M | 48.1M | 32.5M | 33.4M | 30.3M | 26.5M | |
OPERATING INCOME | |||||||
(93.6M) | (80.8M) | (75.3M) | (73.3M) | (57.2M) | (43.3M) | (48.5M) | |
(65.7M) | (57.1M) | (54.5M) | (51.3M) | (39M) | (27.6M) | (30.2M) | |
(27.9M) | (23.7M) | (20.8M) | (21.9M) | (18.2M) | (15.7M) | (18.3M) | |
-16.3M | -21.7M | -27.2M | -40.8M | -23.7M | -13.1M | -22M | |
PRE-TAX INCOME | |||||||
(7.5M) | (8.8M) | (8.5M) | (7.5M) | (7.4M) | (11.5M) | (9.5M) | |
-4.6M | -5.8M | -5.5M | -6M | -7M | -11.4M | -9.2M | |
-5.1M | -5.5M | -5.8M | -6.3M | -12.3M | -11.2M | -7.9M | |
-21.5M | -27.1M | -33M | -47.1M | -36.1M | -24.3M | -30M | |
NET INCOME | |||||||
-21.5M | -27.1M | -33M | -47.1M | -36.1M | -24.3M | -30M |
SEC Filings
NPCE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 12, 2025 | August 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 24, 2025 | June 20, 2025 | 2025 |
Related Guides
Continue your NPCE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.